Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis

Fibrogenesis and Tissue Repair

Volumn 3, Issue 1, 2010, Pages

  Huss, Sebastian ^a   Schmitz, Jörg ^a   Goltz, Diane ^a   Fischer, Hans Peter ^a   Büttner, Reinhard ^a   Weiskirchen, Ralf ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DELPHI STUDY; DISEASE SEVERITY; FIBROGENESIS; IMAGE ANALYSIS; IMAGE PROCESSING; LIVER FIBROSIS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS;

EID: 79958067943     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-3-10     Document Type: Article

References (28)

1. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699. 10.1016/0168-8278(95)80226-6, 7560864.
2. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16. 10.1055/s-2001-12925, 11296695.
3. Diseases of the Bile Ducts. 2007, New York: Churchill Livingstone, Portmann BC, Nakanuma Y, 5.
4. Zaitoun AM, Mardini H, Awad S, Ukabam S, Makadisi S, Record CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol 2001, 54:461-465. 10.1136/jcp.54.6.461, 1731453, 11376020.
5. Caballero T, Perez-Milena A, Masseroli M, O'Valle F, Salmeron FJ, Del Moral RM, Sanchez-Salgado G. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001, 34:740-747. 10.1016/S0168-8278(01)00006-X, 11434621.
6. Dahab GM, Kheriza MM, El-Beltagi HM, Fouda AM, El-Din OA. Digital quantification of fibrosis in liver biopsy sections: description of a new method by Photoshop software. J Gastroenterol Hepatol 2004, 19:78-85. 10.1111/j.1440-1746.2004.03183.x, 14675247.
7. Masseroli M, Caballero T, O'Valle F, Del Moral RM, Perez-Milena A, Del Moral RG. Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol 2000, 32:453-464. 10.1016/S0168-8278(00)80397-9, 10735616.
8. Abdalla AF, Zalata KR, Ismail AF, Shiha G, Attiya M, Abo-Alyazeed A. Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods. Fibrogenesis Tissue Repair 2009, 2:2. 10.1186/1755-1536-2-2, 2682789, 19341455.
9. Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F, Clavien PA. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008, 95:646-656. 10.1002/bjs.6050, 18196571.
10. Johnstone JM, Lee EG. A quantitative assessment of the structural changes the rat's liver following obstruction of the common bile duct. Br J Exp Pathol 1976, 57:85-94.
11. Wang H, Vohra BP, Zhang Y, Heuckeroth RO. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 2005, 42:1099-1108. 10.1002/hep.20903, 16250054.
12. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251. 10.1053/gast.2002.35948, 12360485.
13. Neumeier M, Hellerbrand C, Gabele E, Buettner R, Bollheimer C, Weigert J, Schaffler A, Weiss TS, Lichtenauer M, Scholmerich J, Buechler C. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006, 12:5490-5494.
14. Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, Gressner AM, Weiskirchen R. Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol 2003, 3:29. 10.1186/1471-230X-3-29, 270053, 14565855.
15. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978, 379:103-112. 10.1007/BF00432479, 150690.
16. Nohlgard C, Rubio CA, Kock Y, Hammar H. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993, 28:40-45. 10.1016/0190-9622(93)70006-F, 7678843.
17. O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, Nunes DP. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000, 114:712-718. 10.1309/D7AU-EYW7-4B6C-K08Y, 11068544.
18. Beaussier M, Wendum D, Schiffer E, Dumont S, Rey C, Lienhart A, Housset C. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest 2007, 87:292-303. 10.1038/labinvest.3700513, 17260005.
19. Rubin E, Schaffner F, Popper H. Primary Biliary Cirrhosis. Chronic Non-Suppurative Destructive Cholangitis. Am J Pathol 1965, 46:387-407. 1920366, 14266218.
20. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273. 10.1056/NEJMra043898, 16177252.
21. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut 1986, 27:1373-1376. 10.1136/gut.27.11.1373, 1434080, 3792920.
22. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967, 60:1257-1260. 1901478, 6066569.
23. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001, 121:148-155. 10.1053/gast.2001.25480, 11438504.
24. Park DH, Baik SK, Choi YH, Kim MY, Rhim DW, Kim JW, Kwon SO, Cho MY, Kim CH, Ahn SC. Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats. Korean J Hepatol 2007, 13:61-69.
25. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984, 65:305-311.
26. Cross SS. Grading and scoring in histopathology. Histopathology 1998, 33:99-106. 10.1046/j.1365-2559.1998.00495.x, 9762541.
27. Macnaughton RJ. Numbers, scales and qualitative research. Lancet 1996, 347:1099-1100. 10.1016/S0140-6736(96)90286-X, 8602065.
28. Theise ND BH, Ferrell LD, . (Ed) Acute and chronical viral hepatitis. 2007, New York: Churchill Livingstone, 5, (Ed).